Adam Elhofy, PhD

VP of Research and Innovation
COUR Pharma
Chicago, Illinois, United States

Disclosure information not submitted.

Presentation(s):

• CNP-104, an Antigen-Specific Tolerogenic Nanoparticle Therapy, Stabilizes Prognostic Trajectory and Liver Stiffness with a Link to Reduction in Pathogenic T-Cells in Primary Biliary Cholangitis

  Thursday, June 11, 2026
  5:00 PM - 5:15 PM PST